Albany - NY, Aug. 14, 2015 (GLOBE NEWSWIRE) -- The global endocrine testing market is growing at a CAGR of 4.3% from 2012 to 2019. The market, which was worth US$1.53 billion in 2012, will be worth US$2.03 billion by 2019. The primary cause of growth is considered to be the increasing number of people suffering from infertility, obesity, and diabetes, as stated in the report by Transparency Market Research, "Endocrine Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019".The report dissects the global endocrine testing market according to the various tests performed, including follicle stimulating hormone (FSH), dehydroepiandrosterone sulfate (DHEAS), and thyroid stimulating hormone (TSH). Of these, the report lists thyroid stimulating hormone as the largest market segment in 2012, further estimated to be growing at a CAGR of 5.4% within the forecast period. The prime cause of the segment's accelerated growth is an increasing population of geriatric citizens and their age-related thyroid disorders. The report also cites thyroid problems to be more prevalent in females than in males, giving a ratio of 10:1.
Browse Market Research Report on Endocrine Testing Market:
http://www.transparencymarketresearch.com/endocrine-testing-market.html
Based on diagnostic technologies, the tandem mass spectrometry diagnostic technique was the largest segment of the global endocrine testing market in 2012. The report also names immunoassays and sensor technologies as rapidly growing segments of the global endocrine testing market. The report also cites findings published by Elsevier, Inc., which examine the geriatric population above 65, of which 13.7% have subclinical hypothyroidism and 1.7% have hypothyroidism. Owing to the increasing number of diabetics all over the world, the global endocrine testing market's fastest growing testing segment is set to be the insulin test.
Get Sample Report Copy of Endocrine Testing Market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1645
In terms of end users, the ambulatory care centers segment is set to show the fastest growth rate within the report's forecast period. Top reasons for this segment's growth are a speedier response rate and lower costs than the ones a patient would otherwise incur. The home-based tests segment is also showing promising development opportunities and is predicted to gain a greater market share in the near future. On the other hand, commercial laboratories will continue to gain momentum in terms of revenue generation and consequently invest more in further research. The report also cites information released by the World Health Organization (WHO), in which the WHO states its prediction of diabetes becoming the seventh leading cause of death in the world by 2030. Nearly 80% deaths related to diabetes occur in middle-to-low-income homes, as the disease is exacerbated by poor management.
Browse Press Release of Endocrine Testing Market: http://www.transparencymarketresearch.com/pressrelease/endocrine-testing-market.htm
The report's geographical segmentation ranks Europe as the leader in the global endocrine testing market in 2012. The region was closely followed by North America. Some of the major advancements in endocrine testing have been credited to these regions and their collaborative efforts. Other regions are Asia Pacific and the Rest of the World. The top players in the global endocrine testing market include Agilent Technologies, Thermo Fisher Scientific, Sysmex Corporation, AB SCIEX LLC, and Abbott Laboratories.
Other Reports Published by Transparency Market Research:
- Diabetes Devices and Drugs Market: http://www.transparencymarketresearch.com/diabetes-devices-market.html
- Global and China Insulin Market: http://www.transparencymarketresearch.com/insulin-market.html
- Sterilizers and Surgical, Dental Care and Equipment Disinfectors Market:
http://www.transparencymarketresearch.com/sterilizers-surgical-dental-care-equipment-disinfectors-market.html
Key Segments of the Global Endocrine Testing Market
The global endocrine testing market is segmented into the following categories:
Endocrine Testing Market, by Tests
- Estradiol (E2) Test
- Follicle Stimulating Hormone (FSH) Test
- Human Chorionic Gonadotropin (hCG) Test
- Luteinizing Hormone (LH) Test
- Dehydroepiandrosterone sulfate (DHEAS) Test
- Progesterone Test
- Testosterone Test
- Thyroid Stimulating Hormone (TSH) Test
- Prolactin Test
- Cortisol Test
- Insulin Test
- Others (Gastrin, Thymosin, Secretin, etc.)
Endocrine Testing Market, by Diagnostic Technologies
- Tandem Mass spectrometry
- Immunoassay (Enzyme immunoassays, Radioimmunoassays (RIA)) Technologies
- Monoclonal and Polyclonal Antibody Technologies
- Sensor (Electrochemical, Biosensors, etc.) Technologies
- Clinical Chemistry Technologies
- Others (Liquid Chromatography + Mass Spectrometry (LC-MS), High performance Liquid Chromatography (HPLC), etc.)
Endocrine Testing Market, by End Users
- Hospitals
- Commercial Laboratories
- Ambulatory Care Centers
- Home Based Tests
- Physician Offices
Endocrine Testing Market, by Geography
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Browse Upcoming Market Research Reports:
- Endocrinology Drugs Market: http://www.transparencymarketresearch.com/endocrinology-drugs-market.html
- Neuroendocrine Carcinoma Market: http://www.transparencymarketresearch.com/neuroendocrine-carcinoma-market.html
Browse All Other Pharmaceutical Market Research Reports: http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us:
Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.